Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sometimes it really is appendicitis: case of a CML patient with acute appendicitis.

Annals of hematology·1998
Same author

Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans.

Antimicrobial agents and chemotherapy·1998
Same author

Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.

Leukemia research·1998
Same author

Determinants of increased energy expenditure in HIV-infected women.

The American journal of clinical nutrition·1998
Same author

Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study.

The Journal of clinical endocrinology and metabolism·1998
Same author

Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·1998

Related Experiment Video

Updated: Jul 4, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Hormone therapy for prostate cancer - immediate initiation.

M Schostak1, K Miller, M Schrader

  • 1Department of Urology, Charité Universitätsmedizin Berlin, Berlin , Germany.

Frontiers of Radiation Therapy and Oncology
|June 12, 2008
PubMed
Summary

Early hormone therapy for prostate cancer offers survival benefits and delays symptom progression. It is recommended for aggressive tumors, advanced stages, and patients who may not see their doctors frequently, preventing bone metastasis.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Hormone therapy is a cornerstone in prostate cancer management.
  • The optimal timing for initiating hormone therapy is debated.
  • Long-term treatment carries risks of adverse effects like fatigue and osteoporosis.

Purpose of the Study:

  • To evaluate the benefits and risks of early versus delayed hormone therapy initiation for prostate cancer.
  • To identify patient subgroups that may benefit most from early intervention.
  • To inform treatment decisions considering survival and quality-of-life factors.

Main Methods:

  • Review of existing studies on hormone therapy timing in prostate cancer.
  • Analysis of survival data and clinical symptom development.
  • Consideration of prognostic factors and patient quality of life.

Main Results:

  • Early hormone therapy shows a small but significant survival benefit.
  • Initiating therapy early delays the onset of clinical symptoms.
  • Hormone therapy can prevent bone metastasis, a difficult-to-treat complication.

Conclusions:

  • Early hormone therapy is recommended for men with poorly differentiated or advanced prostate cancer.
  • Treatment decisions should balance survival benefits against potential adverse effects.
  • Early intervention can improve long-term disease control and prevent severe complications.